(lumpectomy/excisional biopsy, mastectomy with reconstruction, mastectomy without reconstruction, axillary lymph node dissection [ALND] , and oncoplastic rearrangement). Details about the use of each pain control option also were collected.
Local anesthesia for excisional biopsies and lumpectomies was used almost unanimously (98%) by survey participants, although less frequently for ALNDs (76%) or mastectomies with or without reconstruction (49% and 55%, respectively). Local anesthesia use was not reported for oncoplastic procedures.
Like local anesthesia, NSAIDs were used by nearly all surgeons (96%) for excisional biopsies or lumpectomies, but less frequently (75%) for mastectomies with reconstruction. NSAID use was not reported for mastectomies without reconstruction or for oncoplastic procedures. For the 56% of respondents who reported using preemptive (immediately preoperative) analgesia, only 57% used NSAIDs. Surgeons who avoid NSAIDs likely worry about hematoma formation, although the literature does not support this concern. 5-7
There was significant variability in the use of regional anesthesia for mastectomies with and without reconstruction despite its documented efficacy. [8] [9] [10] [11] [12] [13] Thirty-three percent of surgeons reported never using nerve blocks for patients undergoing mastectomies with reconstruction, and 43% of surgeons did not use this analgesic strategy at all for patients undergoing mastectomies without reconstruction. The survey, however, did not define ''block'' and presented only the examples of paravertebral, pectoral nerve, and serratus plane blocks. Epidural anesthesia and intercostal nerve blocks, for instance, also are effective modalities for regional pain control. Narcotics were prescribed by approximately 80% of surgeons after excisional biopsies or lumpectomies and by roughly 90% of surgeons after ALNDs or mastectomies with or without reconstruction. Although the majority of surgeons (76%) reported a reduction in the amount of opioids prescribed, there was marked variability in the number of narcotics prescribed for each procedure. Other investigators have found similar inconsistency in the amounts of prescribed postoperative opioids. 3, 14 In a retrospective study of prescribing practices at their institution, Hill et al. reported a median 20 (range 0-50) opioid pills (a pill was defined as the equivalent of 5 mg of oxycodone) prescribed for patients undergoing partial mastectomy (PM) and a median 20 (range 0-60) pills for those undergoing PM with sentinel lymph node biopsy (SLNB). They calculated that opioid requirements could be met for 80% of their patients by prescribing five pills following PM and ten pills following PM with SLNB. 3 In response to a paucity of guidance for postoperative narcotic prescribing, a panel consisting of multiple stakeholders, including surgeons, pain management providers, pharmacists, and patients published a single-institution consensus for quantities of opioids to prescribe for common surgical procedures. PM with and without SLNB were 2 of the 20 general surgery procedures for which the panel made recommendations regarding the range of tablets (defined as 5 mg of oxycodone per tablet) to prescribe: 0-15 with and 0-10 without SLNB. The panel unanimously agreed that all patients should be offered nonnarcotic analgesia and concluded that not prescribing narcotics was a reasonable option for all of these procedures, based on individual factors, including patient preference. 15 Rao et al. make similar recommendations for how many narcotic pain pills to prescribe, depending on the procedure, although the authors do not define the morphine milligram equivalent of a tablet. The only procedures for which the workgroup recommends prescribing more than 10 tablets are ALND (20 or fewer tablets), mastectomy with or without axillary surgery (20 or fewer), and mastectomy with reconstruction (30 or fewer). 5 In addition to making these prescribing recommendations, the ASBrS workgroup encourages the use of regional anesthesia and strongly recommends the use of Enhanced Recovery After Surgery (ERAS) programs. Only a minority (14%) of respondents in this study reported using ERAS protocols. 5 This is a clear opportunity for improving breast surgical care and reducing narcotic use. The authors do not, however, define ERAS or its components, nor do they provide data on whether ERAS use is increasing among the respondents.
The ERAS Ò Society, conceived in 2001, publishes guidelines for multiple specialties, including general, thoracic, orthopedic, urologic, reconstructive, and gynecologic surgery. 16 ERAS provides an evidence-based framework for perioperative care to reduce morbidity and mortality, and it is quickly becoming the standard of care for surgical patients, both in the United States and abroad. [17] [18] [19] [20] [21] A key ERAS recommendation is the use of multimodal analgesia, including preemptive analgesia and regional anesthesia, to reduce the use of perioperative opioids, which contribute to ileus, delayed mobilization, and postoperative nausea and vomiting. Although not intended to prevent opioid dependence, ERAS protocols should help by minimizing the need for narcotics for postoperative pain control. 22 In summary, ERAS is an effective, evidence-based tool widely embraced by other surgical subspecialties and with the potential to reduce opioid requirements of breast surgery patients. I congratulate the ASBrS for addressing the opioid crisis, providing these recommendations, and encouraging the adoption of ERAS pathways. This consensus statement should spark interest in nonopioid analgesia options and educate breast surgeons on the need for ERAS. The next step is for the breast surgery community to define more clearly the pillars of ERAS as they apply to our patients and, ultimately, to measure its impact on patient outcomes, including perioperative opioid needs.
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